SAPHNELO

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Estonia, France, Ireland, Israel, Italy, Japan, Lithuania, Poland, Romania.

Active ingredients

The drug SAPHNELO contains one active pharmaceutical ingredient (API):

1	Anifrolumab UNII 38RL9AE51Q - ANIFROLUMAB
	Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) with high specificity and affinity. This binding inhibits type I IFN signalling thereby blocking the biologic activity of type I IFNs. Inhibition of type I IFN blocks plasma cell differentiation and normalises peripheral T-cell subsets, restoring the balance between adaptive and innate immunity that is dysregulated in SLE.
	Read more about Anifrolumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SAPHNELO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG11		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02522845
EE	Ravimiamet	1876002
FR	Base de données publique des médicaments	61365985
IL	מִשְׂרַד הַבְּרִיאוּת	9034
IT	Agenzia del Farmaco	049964012
JP	医薬品医療機器総合機構	3999462A1028
LT	Valstybinė vaistų kontrolės tarnyba	1094258
PL	Rejestru Produktów Leczniczych	100462345
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68471001
US	FDA, National Drug Code	0310-3040